[go: up one dir, main page]

NL301038I1 - Netarsudil, of een zout of solvaaat daarvan, in het bijzonder netarsudilmesylaat - Google Patents

Netarsudil, of een zout of solvaaat daarvan, in het bijzonder netarsudilmesylaat

Info

Publication number
NL301038I1
NL301038I1 NL301038C NL301038C NL301038I1 NL 301038 I1 NL301038 I1 NL 301038I1 NL 301038 C NL301038 C NL 301038C NL 301038 C NL301038 C NL 301038C NL 301038 I1 NL301038 I1 NL 301038I1
Authority
NL
Netherlands
Prior art keywords
netarsudil
solvate
salt
mesylate
netarsudil mesylate
Prior art date
Application number
NL301038C
Other languages
English (en)
Other versions
NL301038I2 (nl
Original Assignee
Aerie Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43017737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301038(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aerie Pharmaceuticals Inc filed Critical Aerie Pharmaceuticals Inc
Publication of NL301038I1 publication Critical patent/NL301038I1/nl
Publication of NL301038I2 publication Critical patent/NL301038I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL301038C 2009-05-01 2020-04-28 Netarsudil, of een zout of solvaaat daarvan, in het bijzonder netarsudilmesylaat NL301038I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17467209P 2009-05-01 2009-05-01
EP10709100.1A EP2424842B1 (en) 2009-05-01 2010-01-27 Dual mechanism inhibitors for the treatment of disease

Publications (2)

Publication Number Publication Date
NL301038I1 true NL301038I1 (nl) 2020-04-29
NL301038I2 NL301038I2 (nl) 2020-08-17

Family

ID=43017737

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301038C NL301038I2 (nl) 2009-05-01 2020-04-28 Netarsudil, of een zout of solvaaat daarvan, in het bijzonder netarsudilmesylaat

Country Status (9)

Country Link
US (12) US8394826B2 (nl)
EP (5) EP3354643B1 (nl)
JP (5) JP2012525386A (nl)
AU (5) AU2010242800A1 (nl)
CA (3) CA2929545C (nl)
ES (3) ES2834451T3 (nl)
HK (2) HK1225733B (nl)
NL (1) NL301038I2 (nl)
WO (3) WO2010126626A2 (nl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910297B1 (en) 2005-07-11 2016-05-25 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010126626A2 (en) * 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
DK2657227T3 (en) 2010-12-22 2016-08-01 D Western Therapeutics Inst Inc Novel substituted isoquinoline derivative
WO2013104829A1 (en) * 2012-01-13 2013-07-18 Medeia Therapeutics Ltd Novel arylamide derivatives having antiandrogenic properties
WO2014120866A1 (en) * 2013-01-31 2014-08-07 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure or glaucoma
WO2014144781A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
CN114010788A (zh) 2014-08-22 2022-02-08 奥克兰联合服务有限公司 通道调节剂
CN113230021A (zh) 2015-01-12 2021-08-10 科达莱昂治疗公司 微滴递送设备和方法
EP3253433A4 (en) 2015-04-10 2018-08-22 Kedalion Therapeutics, Inc. Piezoelectric dispenser with replaceable ampoule
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2017086941A1 (en) * 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN107434780B (zh) * 2016-05-26 2020-08-07 上海韬勤生物医药科技有限公司 一种ar-13324的制备方法
EP3500251A4 (en) * 2016-08-19 2020-04-08 Aerie Pharmaceuticals, Inc. BETA AMINO ISOCHINOLINYL AMIDE COMPOUNDS
US11389441B2 (en) * 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
KR102122469B1 (ko) 2016-11-01 2020-06-12 주식회사 엘지화학 변성 공액디엔계 중합체 및 이의 제조방법
CA3039106A1 (en) 2017-01-20 2018-07-26 Kedalion Therapeutics, Inc. Piezoelectric fluid dispenser
US10442770B2 (en) 2017-02-02 2019-10-15 Assia Chemical Industries Ltd. Solid state forms of netarsudil mesylate
WO2018159700A1 (ja) 2017-02-28 2018-09-07 興和株式会社 医薬製剤
KR20230124753A (ko) 2017-02-28 2023-08-25 코와 가부시키가이샤 의약품
WO2018159701A1 (ja) 2017-02-28 2018-09-07 興和株式会社 医薬
CN106939011B (zh) * 2017-03-07 2019-11-08 江苏艾立康药业股份有限公司 一种奈他地尔关键中间体的制备方法
CN106939012B (zh) * 2017-03-07 2019-11-08 江苏艾立康药业股份有限公司 一种奈他地尔中间体的制备方法
CN110494138B (zh) 2017-03-27 2023-07-11 兴和株式会社 医药制剂
CN110506037A (zh) * 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
EP3640242B1 (en) * 2017-06-16 2023-04-19 Hitgen Ltd. Rock-inhibiting compound and uses thereof
US11926596B2 (en) 2017-07-21 2024-03-12 Kadmon Corporation, Llc Inhibitors of Rho associated coiled-coil containing protein kinase
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CN111712219A (zh) 2017-12-08 2020-09-25 科达莱昂治疗公司 流体递送对准系统
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
WO2019124487A1 (ja) * 2017-12-21 2019-06-27 参天製薬株式会社 オミデネパグの組合せ
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
WO2019167183A1 (ja) * 2018-02-28 2019-09-06 興和株式会社 医薬品製剤
JP2021517137A (ja) 2018-03-23 2021-07-15 フォチョン・ファーマシューティカルズ・リミテッドＦｏｃｈｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｌｔｄ． Ｒｏｃｋ阻害剤としての重水素化合物
AU2019245390B2 (en) * 2018-03-30 2022-02-17 Alcon Inc. Mono-(acid) salts of 6-aminoisoquinolines and uses thereof
US12186234B2 (en) 2018-04-12 2025-01-07 Bausch + Lomb Ireland Limited Topical ocular delivery methods and devices for use in the same
IT201800007398A1 (it) * 2018-07-20 2020-01-20 Processo per la sintesi di netarsudil dimesilato
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
AU2019328590B2 (en) * 2018-08-31 2023-04-13 Aerie Pharmaceuticals, Inc. Isoquinoline-steroid conjugates and uses thereof
EP3849555A4 (en) 2018-09-14 2022-05-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
JP7257142B2 (ja) * 2018-12-27 2023-04-13 東京応化工業株式会社 化学増幅型感光性組成物、感光性ドライフィルム、パターン化されたレジスト膜の製造方法、鋳型付き基板の製造方法及びめっき造形物の製造方法
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
WO2021001713A1 (en) * 2019-06-29 2021-01-07 Micro Labs Limited Process for the preparation of (s)-netarsudil, its salts & polymorphs
WO2021011873A1 (en) * 2019-07-17 2021-01-21 Percipiad, Inc. Boron-containing rho kinase inhibitors
TWI777325B (zh) * 2019-12-31 2022-09-11 財團法人工業技術研究院 β-胺基酸衍生物、含其之激酶抑制劑與醫藥組成物以及其用途
KR102758256B1 (ko) * 2019-12-31 2025-01-21 인더스트리얼 테크놀로지 리서치 인스티튜트 β-아미노산 유도체, 키나아제 억제제 및 이를 함유하는 약학 조성물
EP3858439A1 (en) 2020-02-03 2021-08-04 Esteve Pharmaceuticals, S.A. Amide derivatives having multimodal activity against pain
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
EP4120973A4 (en) 2020-04-17 2024-04-17 Bausch + Lomb Ireland Limited HYDRODYNAMIC ACTUATED PRESERVATIVE-FREE DISPENSING SYSTEM WITH COLLAPSIBLE LIQUID CONTAINER
US11925577B2 (en) 2020-04-17 2024-03-12 Bausch + Lomb Ireland Limted Hydrodynamically actuated preservative free dispensing system
CN113968816A (zh) * 2020-07-23 2022-01-25 合肥久诺医药科技有限公司 一种异喹啉-5-磺酰氯盐酸盐的制备方法
CN112028827A (zh) * 2020-07-28 2020-12-04 药璞(上海)医药科技有限公司 一种奈他地尔关键中间体的制备方法
MX2023008141A (es) 2021-01-11 2023-10-20 Incyte Corp Terapia combinada que comprende el inhibidor de la vía de proteínas tirosina cinasas de janus cinasas (jak) y el inhibidor de la proteína cinasa asociada a rho (rock).
WO2022235906A1 (en) 2021-05-05 2022-11-10 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
CA3217521A1 (en) * 2021-05-19 2022-11-24 Sven Jacobson Methods of treating depression and anxiety
CA3217563A1 (en) * 2021-05-19 2022-11-24 Thomas Macallister Methods of treating depression and anxiety
JP2025502210A (ja) 2022-01-12 2025-01-24 アルコン，インコーポレイテッド Ｒｏｃｋ阻害剤を調製するための合成中間体および改善したプロセス
WO2024071371A1 (ja) * 2022-09-30 2024-04-04 ユビエンス株式会社 複素環式化合物

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2623228C3 (de) 1976-05-24 1981-09-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide
JPS5587771A (en) * 1978-12-27 1980-07-02 Teikoku Hormone Mfg Co Ltd 1-phenylisoquinoline derivative
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS5993054A (ja) * 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
DK8386A (da) 1986-01-15 1987-07-09 Tpo Pharmachim Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme
DE3622454A1 (de) 1986-07-04 1988-01-07 Guenter Mull Verfahren zur verzerrungsfreien erfassung, untersuchung und identifikation von fingerabdruecken und vorrichtung zur durchfuehrung des verfahrens
ES2036213T3 (es) 1986-10-28 1993-05-16 Smith Kline & French Laboratories Limited Procedimiento para preparar derivados tetrahidroisoquinolin-1-ilicos de acidos carboxilicos.
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH01139528A (ja) 1987-11-24 1989-06-01 Showa Denko Kk 抗潰瘍剤
WO1990002553A1 (en) 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2075082T3 (es) 1989-03-28 1995-10-01 Nisshin Flour Milling Co Derivados de isoquinolina para el tratamiento del glaucoma o hipertension ocular.
KR920008026A (ko) 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
WO1993018028A1 (en) 1992-03-12 1993-09-16 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
WO1998021180A1 (en) 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
WO1997023223A1 (en) 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5866602A (en) 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5814660A (en) 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
DE69714274T3 (de) 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
WO1998020881A1 (en) 1996-11-12 1998-05-22 Alcon Laboratories, Inc 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
WO1998020880A2 (en) 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
JP4248022B2 (ja) 1996-11-12 2009-04-02 アルコン ラボラトリーズ，インコーポレイテッド 眼圧降下剤としての１５―フルオロプロスタグランジン
CA2269853A1 (en) 1996-11-12 1998-05-22 Paul W. Zinke Use of cis-.delta.4 analogs of prostaglandins as ocular hypotensives
CA2276666A1 (en) 1997-03-07 1998-09-11 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
EP1007028A4 (en) 1997-05-09 2002-06-05 TREATING GLAUCOMA WITH 8 ISO PROSTAGLANDINE
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
AU741014B2 (en) 1997-09-09 2001-11-22 Duke University Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists
US5977173A (en) 1997-09-09 1999-11-02 Wos; John August Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists
BR9812631A (pt) 1997-09-09 2000-08-22 Procter & Gamble Tetraidro prostaglandinas substituìdas por c16-c20 aromáticos úteis como agonistas de fp
US5877211A (en) 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
AU1709699A (en) 1997-12-22 1999-07-12 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
AU743607B2 (en) 1998-07-14 2002-01-31 Alcon Laboratories, Inc. Prostaglandin product
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6720175B1 (en) * 1998-08-18 2004-04-13 The Johns Hopkins University School Of Medicine Nucleic acid molecule encoding homer 1B protein
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000071511A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
AU5546000A (en) 1999-06-14 2001-01-02 Protherics Molecular Design Limited Compounds
WO2001037826A1 (fr) 1999-11-26 2001-05-31 Shionogi & Co., Ltd. Antagonistes npyy5
DE60022906T2 (de) 1999-12-28 2006-07-06 Eisai Co., Ltd. Heterozyklische verbindungen mit sulfonamid-gruppen
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
RU2240826C2 (ru) * 2000-02-03 2004-11-27 Эйсай Ко., Лтд. Ингибитор экспрессии интегрина
US6362177B1 (en) * 2000-05-16 2002-03-26 Teijin Limited Cyclic amine derivatives and their use as drugs
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
ES2340362T3 (es) 2000-10-17 2010-06-02 Merck Serono Sa Derivados de sulfanilida farmaceuticamente activos.
US7163800B2 (en) * 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
WO2002069965A1 (en) * 2001-03-05 2002-09-12 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
DE60218445T2 (de) 2001-04-20 2007-11-29 Bayer Pharmaceuticals Corp., West Haven Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
DE60320933D1 (de) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AR038420A1 (es) 2002-02-15 2005-01-12 Glaxo Group Ltd Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
AU2003217870A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pini-modulating compounds and methods of use thereof
CN100525763C (zh) * 2002-03-05 2009-08-12 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
WO2003097795A2 (en) * 2002-05-13 2003-11-27 Norak Biosciences, Inc. Constitutively translocating cell line
WO2004019951A1 (ja) 2002-08-29 2004-03-11 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
CA2496891A1 (en) * 2002-08-30 2004-03-18 Anges Mg, Inc. Novel actin-related cytoskeletal protein lacs
WO2004024717A1 (ja) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬
US7495016B2 (en) 2002-10-21 2009-02-24 Irm Llc Pyrrolidones with anti-HIV activity
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
ES2625341T3 (es) * 2003-06-12 2017-07-19 Astellas Pharma Inc. Derivado de benzamida o sal del mismo
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
JP2007507547A (ja) * 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，７−二置換アザベンゾイミダゾールの調製
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
TWI344961B (en) * 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
JP2005227441A (ja) 2004-02-12 2005-08-25 Konica Minolta Medical & Graphic Inc 光熱写真画像形成材料
US7592357B2 (en) * 2004-02-20 2009-09-22 Smithkline Beecham Corporation Compounds
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EP1756092A4 (en) * 2004-06-17 2009-12-02 Smithkline Beecham Corp NEW INHIBITORS OF RHO-KINASEN
PT1607840E (pt) 2004-06-18 2015-05-20 Tobii Ab Controlo ocular de um computador
RS51362B (en) 2004-08-26 2011-02-28 Pfizer Inc. ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
US20080132507A1 (en) 2004-10-13 2008-06-05 Eisai R&D Management Co., Ltd. Hydrazide Derivatives
UY29198A1 (es) * 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
GB0425026D0 (en) * 2004-11-12 2004-12-15 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
WO2006062982A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
WO2007060028A1 (en) 2004-12-31 2007-05-31 Gpc Biotech Ag Napthyridine compounds as rock inhibitors
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
CA2594915A1 (en) 2005-01-28 2006-08-03 Irm Llc Phenyl-substituted pyrrolidones
WO2006086562A2 (en) * 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
KR20080016604A (ko) * 2005-05-25 2008-02-21 와이어쓰 6-알킬아미노퀴놀린 유도체의 합성 방법
EP1910297B1 (en) * 2005-07-11 2016-05-25 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
US20070135499A1 (en) * 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
CA2620818A1 (en) * 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
WO2007050783A2 (en) * 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
JP2009521494A (ja) 2005-12-22 2009-06-04 アルコン リサーチ， リミテッド ｒｈｏキナーゼ媒介性疾患および状態を治療するための（インダゾール−５−イル）−ピラジンおよび（１，３−ジヒドロインドール−２−オン）−ピラジン
AR057252A1 (es) * 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
AR058885A1 (es) 2005-12-30 2008-02-27 Novartis Ag Compuestos de piperidina 3,5-sustituidos
AU2007209689B2 (en) 2006-01-27 2012-03-15 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
JP5476559B2 (ja) 2006-02-10 2014-04-23 国立大学法人九州大学 リン酸化酵素の新規基質ポリペプチド
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
WO2007100880A1 (en) 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
JP2007246466A (ja) 2006-03-17 2007-09-27 Osaka Univ 中枢神経損傷に対する嗅粘膜移植にＲｈｏキナーゼ阻害剤を用いた神経機能再建法
JPWO2007142323A1 (ja) 2006-06-08 2009-10-29 宇部興産株式会社 側鎖にスピロ環構造を有する新規インダゾール誘導体
US20090318485A1 (en) 2006-07-20 2009-12-24 Kalypsys, Inc. Novel inhibitors of rho kinase
JP2009544625A (ja) 2006-07-20 2009-12-17 メーメット・カーラマン Ｒｈｏキナーゼのベンゾチオフェン阻害剤
US20090247552A1 (en) 2006-07-31 2009-10-01 Shirou Sawa Aqueous liquid preparation containing amide compound
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤
WO2008054599A2 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
WO2008044700A1 (fr) 2006-10-11 2008-04-17 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
US8949825B1 (en) 2006-10-17 2015-02-03 Manageiq, Inc. Enforcement of compliance policies in managed virtual systems
WO2008049000A2 (en) 2006-10-18 2008-04-24 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008049919A2 (en) 2006-10-26 2008-05-02 Devgen N.V. Rho kinase inhibitors
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
WO2008079945A2 (en) 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
CA2673920C (en) 2006-12-27 2015-03-24 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
ES2363105T3 (es) 2006-12-27 2011-07-20 Sanofi-Aventis Isoquinolinas sustituidas y su uso como inhibidores de rho-quinasa.
JP5405315B2 (ja) * 2006-12-27 2014-02-05 サノフイ 置換イソキノリン及びイソキノリノン誘導体
KR101517154B1 (ko) 2006-12-27 2015-04-30 사노피 Ｒｈｏ-키나제의 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
DE602007010981D1 (de) 2006-12-27 2011-01-13 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
ES2625266T3 (es) 2006-12-27 2017-07-19 Sanofi Derivados de isoquinolona sustituidos con cicloalquilamina
MX2009005828A (es) * 2006-12-27 2009-06-16 Sanofi Aventis Derivados de isoquinolona e isoquinolinona sustituidos con cicloalquilamina.
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
WO2008105058A1 (ja) 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
WO2008124665A1 (en) 2007-04-10 2008-10-16 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2551352T3 (es) 2007-07-05 2015-11-18 Array Biopharma, Inc. Pirimido ciclopentanos útiles para el tratamiento de enfermedades inflamatorias o hiperproliferativas
EP2578571B1 (en) 2007-11-16 2015-09-16 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-binding cassette transporters
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010019910A1 (en) 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
WO2010126626A2 (en) * 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CA2764124C (en) 2009-06-19 2016-12-13 D. Western Therapeutics Institute, Inc. Substituted isoquinoline derivative
WO2011085351A2 (en) 2010-01-11 2011-07-14 The Johns Hopkins University Method of treating kcnq related disorders
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
JP2013543862A (ja) 2010-11-08 2013-12-09 ヒールオア・リミテッド 眼科用緩衝組成物およびその使用方法
CN103338772A (zh) 2011-02-04 2013-10-02 兴和株式会社 用于预防或治疗青光眼的药物疗法
JP2013035802A (ja) 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
EP2671883A1 (en) 2012-06-05 2013-12-11 Bioprojet New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
JP2014019650A (ja) 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US20150175534A1 (en) 2012-08-01 2015-06-25 Merck Sharp & Dohme Corp. Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I
CN105051005B (zh) 2012-10-12 2017-06-13 武田药品工业株式会社 环丙胺化合物及其用途
WO2014144781A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
EP3169678A1 (en) 2014-07-17 2017-05-24 Merck Patent GmbH Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
US10227343B2 (en) 2015-01-30 2019-03-12 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9770466B2 (en) 2015-07-02 2017-09-26 Veloce Biopharma, Llc Ophthalmic composition and methods of use
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
EP3500251A4 (en) 2016-08-19 2020-04-08 Aerie Pharmaceuticals, Inc. BETA AMINO ISOCHINOLINYL AMIDE COMPOUNDS
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
AU2019245390B2 (en) 2018-03-30 2022-02-17 Alcon Inc. Mono-(acid) salts of 6-aminoisoquinolines and uses thereof
EP3849555A4 (en) 2018-09-14 2022-05-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Also Published As

Publication number Publication date
HK1225733B (zh) 2017-09-15
WO2010127330A1 (en) 2010-11-04
EP3053913A1 (en) 2016-08-10
US20180244666A1 (en) 2018-08-30
US11028081B2 (en) 2021-06-08
US20130158015A1 (en) 2013-06-20
US20210363141A1 (en) 2021-11-25
US20150175549A1 (en) 2015-06-25
US10654844B2 (en) 2020-05-19
US20180215749A1 (en) 2018-08-02
EP3354643B1 (en) 2020-10-28
EP3354643A1 (en) 2018-08-01
EP3828172A1 (en) 2021-06-02
ES2834451T3 (es) 2021-06-17
EP2424857A1 (en) 2012-03-07
ES2672624T3 (es) 2018-06-15
US8394826B2 (en) 2013-03-12
WO2010127329A1 (en) 2010-11-04
US9951059B2 (en) 2018-04-24
US20200131171A1 (en) 2020-04-30
AU2019210632A1 (en) 2019-08-22
HK1258617A1 (zh) 2019-11-15
US10316029B2 (en) 2019-06-11
EP2424857A4 (en) 2015-11-11
US8716310B2 (en) 2014-05-06
ES2553827T3 (es) 2015-12-14
JP2017160240A (ja) 2017-09-14
EP2424842A2 (en) 2012-03-07
AU2016201754A1 (en) 2016-04-07
JP2012525442A (ja) 2012-10-22
CA2760611A1 (en) 2010-11-04
JP2019142953A (ja) 2019-08-29
WO2010126626A2 (en) 2010-11-04
US20170233381A1 (en) 2017-08-17
JP2016053060A (ja) 2016-04-14
CA2760562C (en) 2016-07-19
US10174017B2 (en) 2019-01-08
JP7057317B2 (ja) 2022-04-19
US20120135984A1 (en) 2012-05-31
EP3053913B1 (en) 2018-03-07
AU2019210632B2 (en) 2021-04-01
EP2424842B1 (en) 2015-10-28
CA2760562A1 (en) 2010-11-04
AU2017248440B2 (en) 2019-05-02
AU2016201754B2 (en) 2017-11-02
CA2929545C (en) 2019-04-09
JP6141385B2 (ja) 2017-06-07
WO2010126626A3 (en) 2010-12-23
NL301038I2 (nl) 2020-08-17
AU2021204320A1 (en) 2021-07-22
US20140187617A1 (en) 2014-07-03
AU2017248440A1 (en) 2017-11-02
CA2929545A1 (en) 2010-11-04
JP2012525386A (ja) 2012-10-22
AU2010242800A1 (en) 2011-12-22
US20200002324A1 (en) 2020-01-02
US20160272589A1 (en) 2016-09-22
US11618748B2 (en) 2023-04-04
AU2010241996A1 (en) 2011-11-24
US20100280011A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
NL301038I1 (nl) Netarsudil, of een zout of solvaaat daarvan, in het bijzonder netarsudilmesylaat
NL301065I2 (nl) Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NL301197I2 (nl) daridorexant of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder daridorexanthydrochloride
NL301234I2 (nl) maralixibat of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder maralixibatchloride
NL301067I2 (nl) Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301096I2 (nl) Filgotinib of een zout daarvan
NL301047I2 (nl) fosnetupitant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder fosnetupitantchloridehydrochloride
NL301028I2 (nl) Gilteritinib of een zout ervan
NL301291I2 (nl) sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301230I2 (nl) Mitapivat, dan wel een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder mitapivatsulfaat
NL301294I2 (nl) Dasiglucagon of een farmaceutisch aanvaardbaar zout of solvaat daarvan, zoals dasiglucagon hydrochloride
NL301187I2 (nl) Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL301035I1 (nl) upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
NL300947I2 (nl) Bictegravir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bictegravirnatrium
NL300876I2 (nl) Alectinib dan wel een zout of solvaat daarvan
BRPI1014920A2 (pt) luva
NL301160I2 (nl) Tasipimidine, optioneel in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder tasipimidine sulfaat
DE102009037898A8 (de) Greifeinrichtung
SMT201400113B (it) Nalmefene cloridrato diidrato
IT1401535B1 (it) Portautensili
EP2508513A4 (en) 2-PYRIDONES COMPOUNDS
EP2705212A4 (en) HOLE MOBILE TOOL
FI20095280A (fi) Kuljetusteline
BRPI1006990A2 (pt) planejador compartilhado
EP2418948A4 (en) ANTISPATTER